Compare Novo Nordisk to its competitors by revenue, employee growth and other metrics at Craft. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.

Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Novo Nordisk net income for the twelve months ending March 31, 2020 was $6.006B, a 4.99% increase year-over-year.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. See Novo Nordisk's revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform. NovoSeven® RT (coagulation Factor VIIa, recombinant) is a drug focused on effective bleed control treatment for your patients with hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann's thrombasthenia with refractoriness to platelets, and acquired hemophilia. Novo Nordisk A/S NVO reported third-quarter 2019 earnings of 64 cents per American Depositary Receipt (ADR), beating the Zacks Consensus Estimate of … Use of their pictures as illustrations is in no way intended to associate them with the promotion of any Novo Nordisk products . Back to NVO Overview ©2019, EDGAR®Online, a division of … Novo Nordisk generates $13K in revenue per employee Novo Nordisk has 12 followers on Owler. Novo Nordisk 2019 revenue: $18.03 billion (122,021 DKK million) 2018 revenue: $16.53 billion (111,831 DKK million) Headquarters: Bagsværd, Denmark See Boxed Warning and Prescribing Info. Novo Nordisk annual/quarterly revenue history and growth rate from 2006 to 2020. Danish pharmaceutical company Novo Nordisk AS (NOVO-B.KO) on Wednesday posted a forecast-beating rise in fourth-quarter revenue, helped by … .

. Novo Nordisk annual net income for 2019 was $5.839B, a … Novo Nordisk net income for the quarter ending March 31, 2020 was $1.757B, a 10.53% increase year-over-year. . Novo Nordisk's main competitors include Abbott, Amgen, Gilead Sciences and The Clinical Trial Center. . Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. Revenue (Quarterly) Yoy Growth is a widely used stock evaluation measure.

Find out the revenue, expenses and profit or loss over the last fiscal year.

Novo Nordisk is a Private company. . Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. of Novo Nordisk . Get the detailed quarterly/annual income statement for Novo Nordisk A/S (NVO). View the latest NVO financial statements, income statements and financial ratios. Novo Nordisk's (NVO) modern insulin portfolio is a major growth revenue driver. In depth view into Novo Nordisk Revenue (Annual) including historical data from 1981, charts, stats and industry comps. . DKK million in net sales million patients reached with Novo Nordisk diabetes products Governance, leadership and shares Responsible business conduct . Novo Nordisk A/S ADR annual stock financials by MarketWatch. Find the latest Revenue (Quarterly) Yoy Growth for Novo Nordisk AS (NVO) Novo Nordisk's top competitors are Eli Lilly, AstraZeneca and Biocon. Novo Nordisk A/S Common Stock (NVO) Revenue EPS ; Previous 3 Years Next 3 Years. . .40 Risk management enables The company markets modern insulin drugs Levemir, NovoRapid, and …